Research programme: methylcarbapenems - Banyu

Drug Profile

Research programme: methylcarbapenems - Banyu

Alternative Names: Anti-MRSA carbapenems research programme - Banyu; Metylcarbapenems research programme - Banyu

Latest Information Update: 13 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Banyu
  • Class Carbapenems
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bacterial infections; Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 13 Mar 2008 No development reported - Preclinical for Bacterial infections in Japan (unspecified route)
  • 13 Mar 2008 No development reported - Preclinical for Meticillin-resistant Staphylococcus aureus infections in Japan (unspecified route)
  • 09 Jan 2002 Preclinical development for Bacterial infections in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top